Floatz logo

Praziquantel

Neurocysticercosis

R-Evolution Worldwide S.r.l. Impresa SocialeSmall moleculePhase 4 / ApprovedActive
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Neurocysticercosis cohort.

Asset / SponsorPhaseRating
Albendazole
R-Evolution Worldwide S.r.l. Impresa Sociale
Phase 4BBB
PBR28
National Institute of Mental Health (NIMH)
Phase 1CC
[F-18]FBR
National Institute of Mental Health (NIMH)
Phase 1CC
DEXAMETHASONE
Johns Hopkins University
N/AD
PHENYTOIN
Johns Hopkins University
N/AD

Same molecule, other indications

Praziquantel is also rated in:

epilepsyDormant
CCC
Indicative ·
55 / 100
View asset →
schistosomiasisDormant
D
Indicative ·
30 / 100
View asset →
fibrotic liver diseaseDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →